Niagara Falls, NY, Sept. 08, 2023 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a number one molecular imaging medical system firm, is happy to announce that the Company will begin its medical examine of its Affinity™ PET-CT imaging system with Ochsner Clinic Foundation in New Orleans, LA. on September 18, 2023.
Positron’s medical examine/analysis will likely be guided by main nuclear heart specialist Dr. Bober, Director of Molecular Imaging and Nuclear Cardiology at Ochsner Health System. The goal of the medical examine is to acquire key information that may symbolize the efficiency and efficacy of Positron’s new state-of-the-art PET-CT imaging system. The medical examine will likely be registered in accordance with the necessities of the International Committee of Medical Journal Editors and follows the necessities of the Institutional Review Board. The preliminary section of the medical examine will encompass phantom testing and subsequent imaging of human sufferers as soon as Positron receives its Investigational Device Exemption from the FDA. In parallel with the medical examine Positron will submit its 510k and Registration to the FDA for clearance to market and promote the Affinity PET-CT.
The medical examine of Positron’s Affinity PET-CT is designed to supply key info that consider the brand new system and its full capabilities with a number of radiopharmaceuticals and new coronary movement software program functions that may improve doctor’s diagnostic evaluation. The outcomes of the medical examine will likely be important for Positron to correctly market and commercialize its Affinity PET-CT.
Adel Abdullah, President of Positron, said, “the start of the clinical study with Dr. Bober and Ochsner Clinic is a significant milestone and one that sets all our plans in motion towards the launch of our PET-CT product. Now with Positron as the device manufacturer we will oversee and direct the many details required for validation, FDA Clearance, and offering of our state-of-the-art PET-CT product to customers.” Mr. Abdullah continued, “becoming the manufacturer required the transfer, organization, preparation and review of thousands of pages of documentation for the Company and FDA and although this was a long process it has worked to our benefit, placing Positron in the best position to capitalize on an expanding nuclear imaging industry that is seeking a molecular imaging scanner that best serves physicians, practices and patients.”
About Positron Corporation
Positron Corporation is a molecular imaging system firm that provides a state-of-the-art PET imaging system and medical providers to nuclear drugs healthcare suppliers all through North America. Positron specializes within the discipline of cardiac Positron Emission Tomography (PET) imaging – the gold customary in cardiac diagnostics. Positron’s revolutionary PET expertise, medical providers and observe options permits healthcare suppliers to precisely diagnose coronary artery illness and enhance affected person outcomes whereas working towards cost efficient drugs.
Positron’s devoted PET system “the Attrius®” and distinctive market place are substantial benefits in facilitating the adoption of cardiac PET and the expansion of the nuclear imaging market.
Positron expects it’s going to quickly supply a state-of-the-art PET-CT molecular imaging system that may allow nuclear cardiologists to make the most of the complete capabilities of molecular imaging and nuclear drugs. Positron’s PET-CT additionally permits the Company to totally service and meet the calls for of the oncology diagnostics market. Positron will proceed to advance and manufacture the expertise by way of its provide, growth, and R&D cooperative with Shenyang Intelligent Neuclear Medical Technology Co, LTD a subsidiary of Neusoft Medical Systems.
Forward-Looking Statements
This press launch incorporates statements which can represent “forward-looking statements” inside the that means of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements embody statements concerning the intent, perception or present expectations of Positron Corporation, and members of its administration in addition to the assumptions on which such statements are based mostly. Words resembling “anticipate,” “if,” “imagine,” “plan,” “estimate,” “anticipate,” “intend,” “could,” “might,” “ought to,” “will,” and comparable expressions are forward-looking statements and contain dangers, uncertainties and contingencies, a lot of that are past our management, which can trigger precise outcomes, efficiency, or achievements to vary materially from anticipated outcomes, efficiency, or achievements. Prospective traders are cautioned that any such forward-looking statements will not be ensures of future efficiency and contain dangers and uncertainties, and that precise outcomes could differ materially from these contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to mirror modified assumptions, the prevalence of unanticipated occasions or adjustments to future working outcomes.
FOR FURTHER INFORMATION, please go to the corporate’s web site at www.positron.com, or contact: [email protected]
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
Lisa Gray, Senior Account Manager
One Rockefeller Plaza, eleventh Floor
New York, NY 10020
Office: (646) 893-5835
Email: [email protected]
